V600E
· 35 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | V600E | “Ameloblastomas are locally aggressive odontogenic tumors that most commonly arise in the mandible and maxilla and often harbor BRAF V600E mutations.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Completion right thyroidectomy with right inferior parathyroidectomy revealed multifocal PTC comprising classical variant foci, a 1.2 cm Warthin-like variant harboring BRAF V600E mutation, and a 0.2 cm follicular variant with NRAS G13R mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “BRAF V600E mutation alone was significantly higher in MDM cases (22.2% vs 10.4%).” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Tovorafenib is a type II RAF inhibitor recently approved by the FDA for relapsed or refractory paediatric low-grade glioma in children aged 6 months and older with BRAF fusions or V600E mutations, owing to its strong central nervous system penetration and absence of paradoxical MAPK pathway activation observed with type I inhibitors.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “BRAF V600E mutation as an indicator of prognosis in papillary thyroid carcinoma or the identification of genetic markers clarifies treatment strategies.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Melanoma, a highly aggressive skin cancer, is often driven by BRAF mutations, such as the V600E mutation, which promotes cancer growth through the MAPK pathway and contributes to treatment resistance.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “TERTp/BRAF V600E was the most prevalent mutation combination (n = 13, 43.3%), followed by TERTp alone (n = 8, 26.7%) and TERTp/RAS (n = 7, 23.4%).” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Variants with strong clinical significance included BRAF V600E (2.32%) and KRAS G12D (18.60%).” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Upon systematic review, the BRAF K601E mutation was identified in 2.8% of PTCs compared to 22% with V600E.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “The most common mutation found in papillary thyroid carcinoma cases is the V600E mutation found in the BRAF gene, yet these patients have a relatively low probability of cancer recurrence.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “The Impact of BRAF V600E Mutation Allele Frequency on the Histopathological Characteristics of Thyroid Cancer.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Results In total, 122 patients (median age, 61 years [IQR, 51-69 years]; 89 men) were included; 78% (95 of 122) had an Eastern Cooperative Oncology Group score of 0, 52% (45 of 86) had an elevated lactate dehydrogenase level, 39% (48 of 122) had a metastatic stage of M1c and 45% (55 of 122) M1d, 45% (55 of 122) had BRAF V600E/K mutation, and the median MTV was 42 mL.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Molecular analysis showed BRAF V600E mutations to be the most frequent, being detected in 45.7% (84/184).” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “No unique factor was correlated with aggressiveness; however, CNA-positive thyroid nodules that were associated with high-risk mutations such as BRAF V600E, TP53, NTRK1/3 fusion, or PTEN mutation with high allele frequency (AF) ended up being aggressive cancers.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “The identification of BRAF-V600E mutation and role of BRAF inhibitors hold promise as a diagnostic tool and treatment modality, respectively, for PXAs, and their relationship to NF-1 is worth further exploration.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Molecular testing revealed BRAF V600E mutations in five cases and NRAS p.Gln61Lys mutation in one case.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “BRAF V600E mutation and 8 types of KRAS mutations were investigated using Real Time PCR.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Seven patients had strong or diffuse BRAF staining having V600E type mutation as major BRAF type mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “RESULTS: Mutations in BRAF V600E and TP53 were detected in our case.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “BI-78D3 promotes apoptosis in BRAF inhibitor-naive and resistant melanoma cells containing a BRAF V600E mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “On subsequent molecular testing, BRAF V600E and V600K mutations were detected in tissues macrodissected from both lesions, respectively.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Furthermore, BRAF V600E mutation is detected in 60% of ECD cases.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “The BRAF(V600E) mutation is found in approximately 40% of papillary thyroid cancers (PTC).” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Papillary thyroid carcinoma (PTC) accounts for >80% thyroid malignancies, and BRAF(V600E) mutation is frequently found in >40% PTC.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Furthermore, the role of the BRAF(V600E) mutation in the clinical outcome of pediatric TC is unknown.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “BRAF mutations, usually V600E, have been reported in 40%-70% of cases, and recently, MAP2K1 mutations have been reported in BRAF-negative cases.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “RESULTS: BRAF gene mutations were seen in 2.5% (19/757) CRC analyzed and BRAF V600E somatic mutation constituted 90% (17/19) of all BRAF mutations.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “RESULTS: BRAF(V600E) was detected in 39 of 82 classic PTC (CPTC) and in all three tall-cell variants (49%, 42/85).” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Point mutations (V600E) in the BRAF oncogene were absent.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “METHODS: Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40 primary melanomas with their matched metastases (n = 42), recurrences (n = 9) and second primaries (n = 4) was performed.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Metastasectomy was performed by pancreaticoduodenectomy followed by sorafenib as genetic testing revealed a BRAF V600E mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “An EUS-guided biopsy confirmed the diagnosis of pancreatic metastasis from PTC, and molecular studies showed positive BRAF(V600E) mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “BRAF(V600E) mutation was detected in 20 of 43 PTCs and all three anaplastic thyroid carcinomas (ATCs).” | 0.82 | literature_variant_regex_v2 |